FY2026 Earnings Estimate for Dynavax Technologies Co. Issued By HC Wainwright (NASDAQ:DVAX)

Dynavax Technologies Co. (NASDAQ:DVAX) – Equities research analysts at HC Wainwright dropped their FY2026 earnings estimates for Dynavax Technologies in a report issued on Monday, October 14th. HC Wainwright analyst E. White now anticipates that the biopharmaceutical company will earn $0.32 per share for the year, down from their prior estimate of $0.33. HC Wainwright has a “Buy” rating and a $29.00 price objective on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.16 per share.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. The firm had revenue of $73.80 million during the quarter, compared to the consensus estimate of $76.92 million. During the same quarter in the previous year, the firm posted $0.03 EPS.

Separately, The Goldman Sachs Group reduced their target price on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $23.67.

Dynavax Technologies Stock Up 2.5 %

NASDAQ DVAX opened at $11.03 on Wednesday. Dynavax Technologies has a 52 week low of $9.74 and a 52 week high of $15.15. The company has a quick ratio of 13.18, a current ratio of 14.18 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $1.44 billion, a P/E ratio of 183.83 and a beta of 1.37. The stock’s 50-day moving average price is $11.05 and its 200-day moving average price is $11.28.

Hedge Funds Weigh In On Dynavax Technologies

Several large investors have recently made changes to their positions in the business. Kynam Capital Management LP raised its stake in Dynavax Technologies by 180.0% during the 1st quarter. Kynam Capital Management LP now owns 4,239,780 shares of the biopharmaceutical company’s stock valued at $52,616,000 after purchasing an additional 2,725,397 shares during the period. Millennium Management LLC bought a new stake in shares of Dynavax Technologies during the second quarter valued at approximately $17,615,000. Great Point Partners LLC lifted its holdings in shares of Dynavax Technologies by 87.7% in the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock worth $26,660,000 after buying an additional 1,109,080 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Dynavax Technologies by 21.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,597,139 shares of the biopharmaceutical company’s stock worth $50,288,000 after acquiring an additional 644,428 shares during the last quarter. Finally, Mizuho Markets Americas LLC boosted its position in shares of Dynavax Technologies by 37.9% during the second quarter. Mizuho Markets Americas LLC now owns 1,175,107 shares of the biopharmaceutical company’s stock worth $13,196,000 after acquiring an additional 323,050 shares during the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.